37
Total Releases
Cordlife Group's Cord Lining, Cord Tissue, Cord Tissue Mesenchymal Stem Cell Release Track Record

The table below features the cord lining, cord tissue or cord tissue mesenchymal stem cell releases performed by Cordlife Group Limited and its subsidiaries.
As a Group, Cordlife has made 37 cord lining, cord tissue or cord tissue mesenchymal stem cell releases, all of which have been used successfully in cellular therapy.
| No | Year of Release | Indication(s) | Unit Used By | Vial Used | STORAGE TIME (MONTHS) | Storage Country | HEALTHCARE INSTITUTION |
|---|---|---|---|---|---|---|---|
| 1 | 2015 | Cerebral Palsy | Self | 1 vial | 7.1 | Indonesia | RS Mayapada |
| 2 | 2016 | Cerebral Palsy | Sibling | 1 vial | 12.3 | Indonesia | RS Harapan Kita / RS Mayapada |
| 3 | 2017 | Dementia | Grandfather | 2 vials | 3.6 | Indonesia | RS Medistra |
| 4 | 2017 | Spina Bifida | Sibling | 1 vial | 10.8 | Indonesia | RS PON |
| 5 | 2018 | Cerebral Palsy | Sibling | 1 vial | 7.7 | Indonesia | RS Cipto Mangunkusumo |
| 6 | 2018 | Diabetes | Grandfather | 1 vial | 16.7 | Indonesia | RS Medistra |
| 7 | 2019 | Kidney Disease | Grandfather | 1 vial | 26.8 | Indonesia | Vinski Regenerative Centre |
| 8 | 2021 | Stroke | Grandfather | 1 vial | 5.5 | Indonesia | Vinski Regenerative Centre |
| 9* | 2022 | Fatty Liver Disease | Father | 1 vial | 17.3 | Philippines | Private hospital, Philippines |
| 10* | 2022 | Chronic Kidney Disease | Grandfather | 2 vials | 17.3 | Philippines | Private hospital, Philippines |
| 11 | 2022 | Cerebral Palsy | Sibling | 1 vial | 10.5 | Indonesia | Private hospital, Indonesia |
| 12* | 2023 | Diabetes Mellitus | Grandmother | 1 vial | 20.0 | Philippines | Private hospital, Philippines |
| 13* | 2023 | Diabetes Mellitus | Uncle | 1 vial | 20.0 | Philippines | Private hospital, Philippines |
| 14* | 2023 | Chronic Kidney Disease | Father | 1 vial | 2.6 | Philippines | Private hospital, Philippines |
| 15* | 2023 | Osteoarthirtis & Diabetes Mellitus | Grandfather | 1 vial | 7.5 | Philippines | Private hospital, Philippines |
| 16 | 2023 | Diabetes Mellitus | Grandfather | 1 vial | 10.5 | Indonesia | Terra Clinic/ Beauty Inc. |
| 17* | 2023 | Chronic Kidney Disease | Uncle | 1 vial | 9.7 | Philippines | Private hospital, Philippines |
| 18 | 2023 | Autism Spectrum Disorder | Sibling | 1 vial | 7.7 | Indonesia | Celltech Stem Cell Centre |
| 19 | 2023 | Symptoms of Speech Delay and Autism | Child | 1 vial | 88.0 | Indonesia | Celltech Stem Cell Centre |
| 20 | 2024 | ASD | Sibling | 2 vials | 10.2 | Indonesia | Jakarta Clinic |
| 21 | 2024 | Symptoms of type II Diabetes Mellitus | Father (of the baby) | 2 vials | 45.9 | Indonesia | Celltech Stem Cell Centre, Jakarta |
| 22 | 2024 | Stroke | Father (of the baby) | 4 vials | 151.2 | Indonesia | Celltech Stem Cell Centre, Jakarta |
| 23 | 2024 | Others | Grandparent (of the baby) | 1 vial | 61.3 | Indonesia | Amnion Clinic, Jakarta |
| 24 | 2024 | Others | Grandparent (of the baby) | 1 vial | 61.3 | Indonesia | Amnion Clinic, Jakarta |
| 25 | 2025 | Others | Grandmother | 2 vials | 10.1 | Indonesia | Amnion Clinic, Jakarta |
| 26 | 2025 | Diabetes Melitus (DM) | Grandfather | 0.67 vials | 24.4 | Indonesia | SCCR, Semarang |
| 27 | 2025 | Allergy | Aunt | 0.67 vials | 24.4 | Indonesia | SCCR, Semarang |
| 28 | 2025 | Post Laminoplasty Cervical | Aunt | 0.67 vials | 24.4 | Indonesia | SCCR, Semarang |
| 29 | 2025 | Kidney Failure | Grandfather | 2 vials | 64.3 | Indonesia | Celltech Stem Cell Centre, Jakarta |
| 30* | 2026 | Others | Grandfather (of the baby) | 6 vials | 21.1 | Philippines | Private hospital, Philippines |
| 31 | 2026 | Autoimmune diseases | Self | 2 vials | 89.3 | Indonesia | Celltech Stem Cell Centre, Jakarta |
| 32* | 2026 | Osteoarthirtis & Diabetes Mellitus | Grandfather (of the baby) | 2 vials | 28.0 | Philippines | Private hospital, Philippines |
| 33* | 2026 | Diabetes Mellitus | Great aunt (of the baby) | 2 vials | 9.0 | Philippines | Private hospital, Philippines |
| 34* | 2026 | Dyslipidemia Diabetes Mellitus | Father (of the baby) | 2 vials | 9.0 | Philippines | Private hospital, Philippines |
| 35 | 2026 | Others | NA | 3 vials | 6.7 | Indonesia | Asia Stem Cell |
| 36* | 2026 | NA | NA | 1 vial | 11.0 | Philippines | Private hospital, Philippines |
| 37* | 2026 | Pre-diabetes | Father (of the baby) | 6 vials | 23.0 | Philippines | Private hospital, Philippines |
*Ready-to-use mesenchymal stem cells stored with Cordlife.
Footnotes:
- This list shows the cord lining, cord tissue or cord tissue mesenchymal stem cells released by Cordlife and its subsidiaries to support the treatment of various diseases. This should not be used as a reference for the list of treatable diseases by cord lining, cord tissue or cord tissue mesenchymal stem cells. In addition, banking your baby’s cord lining, cord tissue or cord tissue mesenchymal stem cells does not guarantee that the stem cells will provide a cure or be applicable for every situation. The use is ultimately determined by the treating physician.
- Some releases may be for the same client but released in different period.
- Indications categorised under "others" included anti-aging therapy (n=4), and wellness (n=1).
DCR 3636
Implementation Date 5-May-2026
Getting Started
Why you should consider umbilical cord lining banking for your baby

Umbilical cord lining stem cells have immune-modulating characteristics. Therefore matching of stem cells between donor and the patient may not be required, which makes them useful both for your baby and other members in the family.

Umbilical cord lining stem cells can also help increase the success rate of stem cell transplant. It contains two types of stem cells – Mesenchymal (MSCs) and Epithelial (EpSCs) Stem Cells, which can be used to support multiple medical treatments whenever needed.

With umbilical cord lining stem cells, your baby and family members will have more treatment options in the future, especially for disorders* that are incurable today such as stroke and heart attack.

Compared to other sources such as bone marrow and adipose tissue, stem cells from umbilical cord lining are younger with better expansion capacity and patients receiving such as stem cells have lower risk of graft versus host disease.

Using cryogenic storage method, umbilical cord lining can remain viable for a long time. This means that the therapeutic value of umbilical cord lining stem cells are well-preserved until the need for treatment arises.

Your baby has one chance to have his/her umbilical cord lining collected as this painless and harmless process must be done at birth.


